Form 4 Filing for BioXcel Therapeutics, Inc.

This Form 4 filing details transactions by Vimal Mehta, CEO and President of BioXcel Therapeutics, Inc. On June 15, 2026, Mr. Mehta acquired 219 shares of Common Stock in a direct transaction. Concurrently, he disposed of 219 Restricted Stock Units (RSUs), with each RSU representing a contingent right to one share of Common Stock. Following these transactions, Mr. Mehta has 69,817 shares of Common Stock directly held. The filing also notes indirect holdings: 125 shares held by his spouse and 480,343 shares held by BioXcel LLC, a subsidiary. Mr. Mehta may be deemed the beneficial owner of the shares held by BioXcel LLC due to his executive roles and board positions within the BioXcel corporate structure, though he disclaims beneficial ownership beyond his pecuniary interest.